Enlighta Inc. Announces Resumption Of Trading

TORTOLA, BVI / ACCESSWIRE / August 27, 2020 / Enlighta Inc. (TSXV:NLTA) (“Enlighta” or the “Company”) announces that the Company was working on a transaction with a confidential private company and with an abundance of caution requested a market halt trading.

At this time, the parties will not continue to pursue the transaction and have discontinued discussions.

Enlighta will continue to pursue and evaluate other businesses and strategic opportunities and will make further announcements with respect to these efforts as soon as practically possible.

Trading of the common shares of the Corporation is expected to resume trading on TSX Venture Exchange (the “TSXV”) subject to regulatory approval, on or about August 28, 2020.

About Enlighta Inc.

Enlighta is a healthcare technology company positioned to provide Artificial Intelligence driven healthcare solutions and enable the transformation of intelligent medical services.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements:

Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of Enlighta. This information and these statements, referred to herein as “forwardlooking statements”, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management’s expectations and intentions with respect to the agreements with Enlighta. These statements generally can be identified by use of forward-looking terms such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. These forwardlooking statements involve numerous risks and uncertainties and actual results might differ materially from results anticipated in any forward-looking statements. Enlighta does not assume any obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements, other than as required by applicable securities laws.

For further information, please contact:

Alan Tam, CPA, CA
CFO, Enlighta Inc.
(604) 200-3803

SOURCE: Enlighta Inc.

View source version on accesswire.com:
https://www.accesswire.com/603639/Enlighta-Inc-Announces-Resumption-Of-Trading

Staff

Recent Posts

Healthcare Triangle, Inc. Announces 1-for-60 Reverse Stock Split as Part of Nasdaq Compliance Plan

PLEASANTON, Calif., Feb. 6, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"),…

5 hours ago

Rokt Joins American Heart Association’s “Go Red. Shop with Heart” Initiative, Marks Kickoff at NYSE Bell Ringing

NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Rokt, the leading ecommerce technology company using machine learning…

5 hours ago

CIMG Inc. Receives 2025 “High-Quality Listed Company Award” Recognition

HONG KONG, Feb. 6, 2026 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: IMG),…

5 hours ago

Airrosti Launches REACH, Bringing a Proven Clinical Breakthrough in Musculoskeletal Care to a National Digital Platform

Validated by Claims Study dated, December,10, 2025, Airrosti providers showed $3.6K+ in savings per member…

5 hours ago

ACG Packaging Materials Joins World Economic Forum’s Global Lighthouse Network as World’s First Pharmaceutical Packaging Company

DAVOS, Switzerland and MUMBAI, India, Feb. 6, 2026 /PRNewswire/ -- ACG Packaging Materials today announced…

5 hours ago

CaseBioscience® Launches CaseCryo® CTG DMSO and CaseStor® HSS at ATW 2026, Advancing Next-Generation Biopreservation for Cell Therapy

Introducing cell therapy–grade cryopreservation and hypothermic storage solutions designed for consistency, quality, and performance across…

5 hours ago